Abstract 1489P
Background
In light of the expanding utilization of electronic patient-reported outcomes (ePROs) in healthcare settings, their integration into the standard practice of palliative care remains uncertain. This investigation aimed to identify the determinants linked with adherence to ePRO utilization within a Cancer Network in Brazil.
Methods
Eligible patients had metastatic solid cancer with an expected survival of over 3 months. They were enrolled in monthly ePRO assessments using the Integrated Palliative Outcome Scale (IPOS). Patients failing to complete assessments received one reminder. We conducted multivariate regression analyses to examine the factors influencing adherence. Patient characteristics (age, gender, marital status, education level, and cancer type), along with initial responses on the IPOS, were included as predictors. Follow-up time within palliative care was controlled for in the analysis.
Results
A total of 494 patients were included, with a median age of 67 years (range: 22-94). Most were female (56.1%), married (58.9%), and had at least high school education (77.7%). Most were diagnosed with gastrointestinal (33.2%), breast (20.2%), and genitourinary (14.8%) cancers. Patients had a median follow-up time within palliative care of 10.5 months (range: 3-63 months). Notably, younger age (β=-0.3, SE=0.01, p=0.004), female gender (β=-0.7, SE=0.36, p=0.03) and higher education (β =0.1, SE = 0.06, p = 0.009) were associated with higher ePRO adherence. Interestingly, lower initial assessment score was linked with increased ePRO adherence (p=0.002). Patients experiencing loss of appetite (β=0.4, SE=0.18, p=0.01), having an anxious family member (β=0.3, SE=0.16, p=0.03), and expressing a desire for more information (β=0.2, SE=0.11, p=0.04) also demonstrated higher ePRO adherence.
Conclusions
Our findings underscore the need for tailored approaches to promote patient engagement and improve adherence to ePRO assessments in palliative care settings. Further research exploring interventions targeted at addressing these factors could enhance the integration of ePRO into routine clinical practice, ultimately leading to better patient outcomes and quality of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10